Metronomic chemotherapy: changing the paradigm that more is better
The introduction of the “maximum tolerated dose” in usual treatment protocols (and its concomitant overt toxicity) made necessary the imposition of rest periods between cycles of therapy—a practice that not only involves re-growth of tumour cells, but also growth of selected clones resistant to the...
Guardado en:
| Autores principales: | Scharovsky, O. Graciela, Mainetti, Leandro Ernesto, Rozados, Viviana R. |
|---|---|
| Formato: | article artículo publishedVersion |
| Lenguaje: | Inglés |
| Publicado: |
Multimed Inc.
2012
|
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/2133/2008 http://hdl.handle.net/2133/2008 |
| Aporte de: |
Ejemplares similares
-
Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response
por: Perroud, Herman A, et al.
Publicado: (2018) -
Clinical response in patients with ovarian cancer treated with metronomic chemotherapy
por: Perroud, Herman A, et al.
Publicado: (2018) -
The Immune Response and the Therapeutic Effect of Metronomic Chemotherapy With Cyclophosphamide
por: Rozados, Viviana R., et al.
Publicado: (2012) -
Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
por: Perroud, Herman A, et al.
Publicado: (2018) -
Comparative Effectiveness of Two Metronomic Chemotherapy Schedules. Our Experience in the Preclinical Field
por: Rico, María José, et al.
Publicado: (2018)